Does Rallies show 13F holders for INCY?

Yes. Rallies tracks hedge fund and 13F ownership data for INCY, including fund names, share counts, latest tracked quarter, and position changes when available.

Is INCY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INCY. It does not provide personalized investment advice.

INCY (Incyte) Stock Analysis - Hedge Fund Holdings

Incyte (INCY) is a publicly traded Healthcare sector company. As of May 20, 2026, INCY trades at $97.40 with a market cap of $19.02B and a P/E ratio of 36.15. INCY moved +1.56% today. Year to date, INCY is -5.74%; over the trailing twelve months it is +49.82%. Its 52-week range spans $53.56 to $112.29. Analyst consensus is buy with an average price target of $109.13. Rallies surfaces INCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns INCY stock?

Hedge funds tracked by Rallies that own INCY include Panagora Asset, Bridgewater Associates, Pinebridge Investments, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Incyte.

INCY Key Metrics

Key financial metrics for INCY
Metric	Value
Price	$97.40
Market Cap	$19.02B
P/E Ratio	36.15
EPS	$2.67
Dividend Yield	0.00%
52-Week High	$112.29
52-Week Low	$53.56
Volume	704.20K
Avg Volume	0
Revenue (TTM)	$3.70B
Net Income	$597.60M
Gross Margin	93.10%

Top Hedge Funds Holding INCY

Panagora Asset holds 1.21M shares of INCY, changed +22.05% as of Mar 31, 2026.
Bridgewater Associates holds 130.30K shares of INCY, changed -60.35% as of Mar 31, 2026.
Pinebridge Investments holds 37.99K shares of INCY, changed -15.29% as of Sep 30, 2025.
Eisler Capital holds 12.54K shares of INCY, changed +0.00% as of Mar 31, 2024.

Latest INCY News

Incyte to Present 20+ Abstracts Highlighting Hematology Pipeline at EHA 2026 Congress — May 12, 2026
Incyte drops on 2026 revenue guidance shortfall despite Q1 earnings beat — Apr 30, 2026
Incyte jumps after Q1 revenue surge, upbeat pipeline and guidance reaffirmation — Apr 29, 2026
Incyte Gains FDA Acceptance for HS Therapy, Eyes 1H27 Vitiligo Filing — Apr 29, 2026
Incyte slides after Q1 beat as 2026 revenue guidance misses estimates — Apr 28, 2026

Recent INCY Insider Trades

CAGNONI PABLO J sold 18.67K (~$1.80M) on Apr 17, 2026.
CAGNONI PABLO J sold 18.67K (~$1.76M) on Mar 17, 2026.
CAGNONI PABLO J sold 18.67K (~$1.88M) on Feb 19, 2026.

INCY Analyst Consensus

17 analysts cover INCY: 0 strong buy, 8 buy, 8 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $109.13.

Common questions about INCY

Who owns INCY stock?: Hedge funds tracked by Rallies that own INCY include Panagora Asset, Bridgewater Associates, Pinebridge Investments, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Incyte.
Does Rallies show 13F holders for INCY?: Yes. Rallies tracks hedge fund and 13F ownership data for INCY, including fund names, share counts, latest tracked quarter, and position changes when available.
Is INCY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INCY. It does not provide personalized investment advice.